Photos: FDA Clears Hologic R2(TM) DigitalNow(TM) HD Software Application

Software processes digitized prior film mammograms to produce DICOM images
that more closely resemble digital mammograms

BEDFORD, Mass., June 16 /PRNewswire-FirstCall/ -- Hologic, Inc. (Hologic or
the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of
premium diagnostics, medical imaging systems and surgical products dedicated
to serving the healthcare needs of women, today announced that it has received
Food and Drug Administration (FDA) clearance for its R2(TM) DigitalNow(TM) HD
software application.

To view the Multimedia News Release, go to:
http://www.prnewswire.com/mnr/hologic/38828/

The R2 DigitalNow HD software is the only FDA-cleared application intended to
process digitized screen-film mammograms for comparison purposes. The product
is now available worldwide.

By collaborating with radiologists to understand the demands of reading
digital mammograms, Hologic created the R2 DigitalNow HD software, which
adapts each digitized film image to a selected contrast and tissue intensity
that models a digital mammography system. It also embeds a series of look-up
tables in the image that allow Integrated Healthcare Enterprise (IHE)
mammography conformant workstations to draw out less evident regions of
density within digitized films.(1)

"The DigitalNow HD software is designed to enhance workflow by promoting
consistency in the digital mammography reading environment," said Julian
Marshall, director, R2 product management & principal engineer at Hologic.
"One of the most powerful capabilities of this product is that images already
digitized by R2 DigitalNow software and stored in PACS can be routed to R2
DigitalNow HD and reprocessed."

About Hologic, Inc.
Hologic, Inc. is a leading developer, manufacturer and supplier of premium
diagnostics products, medical imaging systems and surgical products dedicated
to serving the healthcare needs of women. Hologic's core business units are
focused on breast health, diagnostics, GYN surgical, and skeletal health.
Hologic provides a comprehensive suite of technologies with products for
mammography and breast biopsy, radiation treatment for early-stage breast
cancer, cervical cancer screening, treatment for menorrhagia, osteoporosis
assessment, preterm birth risk assessment, mini C-arm for extremity imaging
and molecular diagnostic products including HPV and reagents for a variety of
DNA and RNA analysis applications. For more information, visit
www.hologic.com.

Hologic, DigitalNow, and R2 are trademarks and/or registered trademarks of
Hologic, Inc., and/or its subsidiaries in the United States and/or other
countries. All other trademarks and registered trademarks are the property of
their respective owners.

Forward Looking Statement Disclaimer
This News Release may contain forward-looking information that involves risks
and uncertainties, including statements about the effect and adoption of the
use of the R2 Digital Now system. There can be no assurance that the system
will achieve the benefits described herein and that such benefits will be
replicated in any particular manner with respect to an individual patient as
the actual effect of the use of the R2 Digital Now system can only be
determined on a case-by-case basis depending on the particular circumstances
of the procedure and patient in question. Thus there can be no assurance of
general adoption of this technology by the medical community. Hologic
expressly disclaims any obligation or undertaking to release publicly any
updates or revisions to the data or statements presented herein to reflect any
change in the Company's expectations or any change in events, conditions or
circumstances on which any such data or statements are based. Certain factors
that could adversely affect the Company's business and prospects are described
in Hologic filings with the Securities and Exchange Commission.

(1) The "IHE Mammo" profile defines the necessary mammography requirements for
the display quality, behavior, layout and annotation of prior and current
mammography image for diagnostic workstations.

Press Contacts:
Jim Culley
Director, Marketing
Hologic, Inc.
+1.781.999.7583
Jim.culley@hologic.com

Olga Karagiannis
Senior Specialist, Publicity & Advertising
Hologic, Inc.
+1.781.761.7069
Olga.karagiannis@hologic.com

SOURCE Hologic, Inc.

Jim Culley, Director, Marketing of Hologic, Inc., +1-781-999-7583,
Jim.culley@hologic.com; or Olga Karagiannis, Senior Specialist, Publicity &
Advertising of Hologic, Inc., +1-781-761-7069, Olga.karagiannis@hologic.com